Screening and exploration of neoadjuvant “de-escalation” therapy for early breast cancer

Patients with operable cStage II-IIIA breast cancer who achieved pCR after a short period of neoadjuvant chemotherapy have a satisfactory prognosis and may be suitable for chemotherapy "de-escalation." This approach is also a dominant application of neoadjuvant "tailoring therapy."

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2025-03-25
DOI
https://doi.org/10.3389/fphar.2025.1574665
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Screening and exploration of neoadjuvant “de-escalation” therapy for early breast cancer

Bingqi Xu, Zhenfeng Huang, Xinhang Liu, Li Song et al.
1 links
Frontiers in Pharmacology
Breast Cancer Treatment Studies
article

Screening and exploration of neoadjuvant “de-escalation” therapy for early breast cancer

Bingqi Xu, Zhenfeng Huang, Xinhang Liu, Li Song, Fei Gao, Nana Zhang, Abiyasi Nanding, Jiawei Zhang, Peng Zhang, Guoqiang Zhang, Jian Zhang, Mingyang Liu, Rui Li, Wenli Kang, Ming Shan, Qi Jiang, Zibo Shen
article en

Abstract

Patients with operable cStage II-IIIA breast cancer who achieved pCR after a short period of neoadjuvant chemotherapy have a satisfactory prognosis and may be suitable for chemotherapy "de-escalation." This approach is also a dominant application of neoadjuvant "tailoring therapy."

Frontiers in PharmacologyVol. 16
Jiamusi University (CN), Harbin Medical University (CN), Shenzhen University (CN), King's College London (GB), First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN), Third Affiliated Hospital of Harbin Medical University (CN), Daqing Oilfield General Hospital (CN), Dalian Municipal Central Hospital (CN), Baotou Teachers College (CN), Qujiang People's Hospital (CN), Shenzhen Third People’s Hospital (CN)
Good health and well-being
Openalex Percentile: Top 93%
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Screening and exploration of neoadjuvant “de-escalation” therapy for early breast cancer — Bingqi Xu, Zhenfeng Huang, et al. · Frontiers in Pharmacology (2025) | TGRS Research Map | TGRS